Skip to main content
Dinesh Khanna, MD, Rheumatology, Ann Arbor, MI

Dinesh Khanna MD


Frederick GL Huetwell Professor of Medicine, Director, Scleroderma Program, University of Michigan

Join to View Full Profile
  • 1500 E Medical Center Dr3rd Floor Taubman Center Recp AAnn Arbor, MI 48105

  • Phone+1 734-647-5900

Dr. Khanna is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
  • Connect with colleagues in the same hospital or clinic.
  • Read the latest clinical news, personalized to your specialty.

Summary

  • I am board certified in rheumatology and direct the University of Michigan Scleroderma Program.

Education & Training

  • UCLA David Geffen School of Medicine/UCLA Medical Center
    UCLA David Geffen School of Medicine/UCLA Medical CenterFellowship, Rheumatology, 2000 - 2003
  • Wright State University
    Wright State UniversityResidency, Internal Medicine, 1997 - 2000
  • Delhi University College of Medical Sciences
    Delhi University College of Medical SciencesClass of 1996

Certifications & Licensure

  • MI State Medical License
    MI State Medical License 2011 - 2027
  • OH State Medical License
    OH State Medical License 1999 - 2008
  • Rheumatology
    American Board of Internal Medicine Rheumatology

Awards, Honors, & Recognition

  • CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2012-2013
  • Fellow (FACR) American College of Rheumatology

Clinical Trials

Publications & Presentations

PubMed

Journal Articles

  • Reply  
    Dinesh Khanna, Elana J Bernstein, David J Lederer, Arthritis & Rheumatology
  • Ongoing Clinical Trials and Treatment Options for Patients with Systemic Sclerosis–Associated Interstitial Lung Disease  
    Donald P Tashkin, Dinesh Khanna, Rheumatology
  • Safety and Efficacy of Subcutaneous Tocilizumab in Systemic Sclerosis: Results from the Open-Label Period of a Phase II Randomised Controlled Trial (faSScinate)  
    Dinesh Khanna, Daniel Eric Furst, Emergency Medicine Journal

Press Mentions

  • Arthritis Drug Shows Promise Against Autoimmune Disease Scleroderma
    Arthritis Drug Shows Promise Against Autoimmune Disease SclerodermaOctober 11th, 2022
  • How the Western Diet and Gut Bacteria Can Lead to Scarring, Vessel Damage in Scleroderma
    How the Western Diet and Gut Bacteria Can Lead to Scarring, Vessel Damage in SclerodermaAugust 23rd, 2022
  • Two Steps Forward, One Step Back: Hunting for a Game-Changer in Scleroderma
    Two Steps Forward, One Step Back: Hunting for a Game-Changer in SclerodermaMarch 22nd, 2022
  • Join now to see all

Professional Memberships

Viewing the full profile is available to verified healthcare professionals only.

Find your profile and take control of your online presence: